# 🚨 NOVO NORDISK SUES HIMS & HERS — Patent attorney Gaston Kroub breaks it down

Page: https://stenobird.com/podcast/hims-house-7026583/novo-nordisk-sues-hims-hers-patent-attorney-gaston-kroub-breaks-it-down
Text version: https://stenobird.com/podcast/hims-house-7026583/novo-nordisk-sues-hims-hers-patent-attorney-gaston-kroub-breaks-it-down.md
Podcast: [Hims House](https://stenobird.com/podcast/hims-house-7026583)
Published: 2026-02-10T21:23:51+00:00
Episode link: https://podcasters.spotify.com/pod/show/jonathan-stern1/episodes/NOVO-NORDISK-SUES-HIMS--HERS--Patent-attorney-Gaston-Kroub-breaks-it-down-e3etpep
Audio file: https://anchor.fm/s/10e9c0874/podcast/play/115319705/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2026-1-10%2F417857260-44100-2-0b1030db6685a.mp3
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/hims-house-7026583/episodes/novo-nordisk-sues-hims-hers-patent-attorney-gaston-kroub-breaks-it-down
Duration seconds: 3312

## Resource

Thanks to our partner, Mochi Health! https://JoinMochi.com In this episode of Hims House, Jonathan Stern is joined by patent attorney Gaston Kroub to break down Novo Nordisk’s Delaware lawsuit accusing Hims of infringing the semaglutide “343” patent (U.S. Patent No. 8,129,343). They discuss what Novo is actually asking the court for (a reasonable royalty, damages, and a permanent injunction), what Novo has to prove, and what levers Hims has to fight back. Gaston explains why Novo didn’t seek a preliminary injunction at filing, why that may be intentional, and how venue, jury dynamics, and Delaware court congestion may shape the case timeline. They also get into the downside scenarios for Hims, possible defenses and mitigation strategies (invalidity, damages limitations, indemnification), and how parallel FDA and DOJ pressure could influence the broader future of compounded GLP-1s. 02:25 The lawsuit and what Novo is seeking: royalties, damages, injunction 07:41 Why no preliminary injunction filed 12:31 Why did Novo file now vs. 8-9 months ago? 24:04 Why did Novo file in Delaware? 29:21 Likely timelines, chances of settlement or dismissal 33:20 Worst-case scenarios 36:48 Indemnification and supplier liability? 45:01 FDA & DOJ pressure on compounded GLP-1s 49:46 How Hims miscalculated the oral launch 55:00 What to watch next Disclaimer: This podcast is for informational and entertainment purposes only. Nothing discussed should be considered financial, investment, or legal advice. Always consult with a qualified professional before making financial decisions.

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/hims-house-7026583/episodes/novo-nordisk-sues-hims-hers-patent-attorney-gaston-kroub-breaks-it-down/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/hims-house-7026583/novo-nordisk-sues-hims-hers-patent-attorney-gaston-kroub-breaks-it-down.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.